Why it Matters: After a year-long lobbying hiatus, InductiveHealth Informatics Inc. has made a strategic pivot by hiring BGR Government Affairs. This decision comes at a critical time coinciding with pandemic preparedness legislation awaiting congressional action.
By the Numbers: In 2023, InductiveHealth spent $90,000 on lobbying prior to going silent in 2024. They have now engaged three experienced lobbyists from BGR Government Affairs LLC: Marvin B. Figueroa, Christopher P. Kelly, and Robert D. Walton. Notably, BGR generated $32.5 million in lobbying revenue over the past year, leveraging their expertise in healthcare, technology, and government contracting.
Why Now: The urgency of pandemic preparedness has been underscored by numerous disease outbreaks in 2024, which exposed critical surveillance gaps. Recent incidents, such as H5N1 bird flu transmissions and new mpox variants sparking global concern, highlight the pivotal role of InductiveHealth’s technology.
The Agenda: InductiveHealth is focusing its efforts on disease surveillance and legislation pertaining to pandemic preparedness. Their main objective is the reauthorization of the Pandemic and All-Hazards Preparedness Response Act (PAHPA). Although several PAHPA provisions have been extended until September 2025, comprehensive reauthorization is still pending.
Competitive Landscape: BGR’s roster includes other health tech clients like Real Time Medical Systems LLC, bioMérieux Inc., and InterSystems Corp.. This situation presents both strategic synergies and potential conflicts within the client’s portfolio, particularly regarding PAHPA lobbying efforts.
Between The Lines: Recent outbreaks have generated favorable political momentum for increased investments in surveillance. The CDC’s modernization of the National Electronic Disease Surveillance System further showcases this shift. With strong bipartisan support for pandemic preparedness funding, especially in light of lessons learned from the COVID-19 pandemic, InductiveHealth’s proactive approach strategically positions them ahead of the fiscal 2026 budget discussions and the PAHPA September deadline.
The Bottom Line: InductiveHealth’s revival in lobbying suggests a calculated strategy aimed at capitalizing on anticipated federal spending in response to recent disease outbreaks and forthcoming legislation. Their innovative technologies are poised to fill critical gaps in pandemic response efforts.
Spot something wrong? Report an issue with this article